Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 908

1.

Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.

Fleischmann R, Genovese MC, Lin Y, St John G, van der Heijde D, Wang S, Gomez-Reino JJ, Maldonado-Cocco JA, Stanislav M, Kivitz AJ, Burmester GR.

Rheumatology (Oxford). 2019 Jul 15. pii: kez265. doi: 10.1093/rheumatology/kez265. [Epub ahead of print]

PMID:
31312844
2.

Low specificity but high sensitivity of inflammatory back pain criteria in rheumatology settings in Europe: confirmation of findings from a German cohort study.

de Hooge M, van Gaalen FA, Renson T, De Craemer AS, van de Sande MG, Ramonda R, Fagerli KM, Jacobsson LTH, van der Heijde D, Elewaut D, Van den Bosch F.

Ann Rheum Dis. 2019 Jul 13. pii: annrheumdis-2019-215742. doi: 10.1136/annrheumdis-2019-215742. [Epub ahead of print] No abstract available.

PMID:
31302595
3.

Associations of lumbar scoliosis with presentation of suspected early axial spondyloarthritis.

Voirin-Hertz M, Carvajal Alegria G, Garrigues F, Simon A, Feydy A, Reijnierse M, van der Heijde D, Loeuille D, Claudepierre P, Marhadour T, Saraux A.

Semin Arthritis Rheum. 2019 Jun 13. pii: S0049-0172(19)30198-2. doi: 10.1016/j.semarthrit.2019.06.008. [Epub ahead of print]

PMID:
31277929
4.

Development of one general and six country-specific algorithms to assess societal health utilities based on ASAS HI.

Essers I, Hiligsmann M, Kiltz U, Bansback N, Braun J, van der Heijde D, Boonen A.

RMD Open. 2019 May 21;5(1):e000872. doi: 10.1136/rmdopen-2018-000872. eCollection 2019.

5.

Spinal-pelvic orientation: potential effect on the diagnosis of spondyloarthritis.

Carvajal Alegria G, Deloire L, Herbette M, Garrigues F, Gossec L, Simon A, Feydy A, Reijnierse M, van der Heijde D, Loeuille D, Claudepierre P, Marhadour T, Saraux A.

Rheumatology (Oxford). 2019 Jun 24. pii: kez240. doi: 10.1093/rheumatology/kez240. [Epub ahead of print]

PMID:
31236597
6.

Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison.

Braun J, Haibel H, de Hooge M, Landewé R, Rudwaleit M, Fox T, Readie A, Richards HB, Porter B, Martin R, Poddubnyy D, Sieper J, van der Heijde D.

Arthritis Res Ther. 2019 Jun 7;21(1):142. doi: 10.1186/s13075-019-1911-1.

7.

Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis.

van der Heijde D, Schiff M, Tanaka Y, Xie L, Meszaros G, Ishii T, Casillas M, Ortmann RA, Emery P.

RMD Open. 2019 May 10;5(1):e000898. doi: 10.1136/rmdopen-2019-000898. eCollection 2019.

8.

Correction: HLA-C*07 in axial spondyloarthritis: data from the German Spondyloarthritis Inception Cohort and the Spondyloarthritis Caught Early cohort.

de Winter JJ, Blijdorp IC, de Jong HM, Sauter J, Schmidt AH, van Gaalen FA, van der Heijde D, Poddubnyy D, Yeremenko NG, van de Sande MG, Baeten DL.

Genes Immun. 2019 May 9. doi: 10.1038/s41435-019-0076-x. [Epub ahead of print]

PMID:
31068685
9.

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial.

Takeuchi T, Tanaka Y, Soen S, Yamanaka H, Yoneda T, Tanaka S, Nitta T, Okubo N, Genant HK, van der Heijde D.

Ann Rheum Dis. 2019 Jul;78(7):899-907. doi: 10.1136/annrheumdis-2018-214827. Epub 2019 Apr 29.

10.

Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?

van Lunteren M, van der Heijde D, Sepriano A, Berg IJ, Dougados M, Gossec L, Jacobsson L, Ramonda R, Rudwaleit M, Sieper J, Landewé R, van Gaalen FA.

Rheumatology (Oxford). 2019 Apr 1. pii: kez095. doi: 10.1093/rheumatology/kez095. [Epub ahead of print]

PMID:
30938446
11.

Percentage of progressors in imaging: can we ignore regressors?

Sepriano A, Ramiro S, Landewé R, Dougados M, van der Heijde D.

RMD Open. 2019 Feb 26;5(1):e000848. doi: 10.1136/rmdopen-2018-000848. eCollection 2019.

12.

Measuring spinal mobility in early axial spondyloarthritis: does it matter?

Marques ML, Ramiro S, Goupille P, Dougados M, van Gaalen F, van der Heijde D.

Rheumatology (Oxford). 2019 Mar 16. pii: kez026. doi: 10.1093/rheumatology/kez026. [Epub ahead of print]

PMID:
30879078
13.

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients.

Humby F, Lewis M, Ramamoorthi N, Hackney JA, Barnes MR, Bombardieri M, Setiadi AF, Kelly S, Bene F, DiCicco M, Riahi S, Rocher V, Ng N, Lazarou I, Hands R, van der Heijde D, Landewé RBM, van der Helm-van Mil A, Cauli A, McInnes I, Buckley CD, Choy EH, Taylor PC, Townsend MJ, Pitzalis C.

Ann Rheum Dis. 2019 Jun;78(6):761-772. doi: 10.1136/annrheumdis-2018-214539. Epub 2019 Mar 16.

14.

Systematic review of rheumatoid arthritis clinical studies: Suboptimal statistical analysis of radiological data.

Mahmood S, van Tuyl L, Schoonmade LJ, Landewé R, van der Heijde D, Twisk J, Boers M.

Semin Arthritis Rheum. 2019 Feb 21. pii: S0049-0172(18)30507-9. doi: 10.1016/j.semarthrit.2019.02.009. [Epub ahead of print] Review.

PMID:
30878153
15.

A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis.

Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landewé R, Rudwaleit M, Hall S, Bauer L, Hoepken B, de Peyrecave N, Kilgallen B, van der Heijde D.

Arthritis Rheumatol. 2019 Jul;71(7):1101-1111. doi: 10.1002/art.40866. Epub 2019 May 28.

PMID:
30848558
16.

Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab.

van der Heijde D, Gladman DD, FitzGerald O, Kavanaugh A, Graham D, Wang C, Fallon L.

J Rheumatol. 2019 Mar 1. pii: jrheum.180971. doi: 10.3899/jrheum.180971. [Epub ahead of print]

17.

Impact of patient global assessment on achieving remission in patients with rheumatoid arthritis: a multinational study using the METEOR database.

Ferreira RJO, Carvalho PD, Ndosi M, Duarte C, Chopra A, Murphy E, van der Heijde D, Machado PM, da Silva JAP.

Arthritis Care Res (Hoboken). 2019 Mar 1. doi: 10.1002/acr.23866. [Epub ahead of print]

PMID:
30821895
18.

HLA-C*07 in axial spondyloarthritis: data from the German Spondyloarthritis Inception Cohort and the Spondyloarthritis Caught Early cohort.

de Winter JJ, Blijdorp IC, de Jong HM, Sauter J, Schmidt AH, van Gaalen FA, van der Heijde D, Poddubnyy D, Yeremenko NG, van de Sande MG, Baeten DL.

Genes Immun. 2019 Feb 26. doi: 10.1038/s41435-019-0061-4. [Epub ahead of print] Erratum in: Genes Immun. 2019 May 9;:.

PMID:
30809016
19.

Preliminary Definitions for Sacroiliac Joint Pathologies in the OMERACT Juvenile Idiopathic Arthritis Magnetic Resonance Imaging Score (OMERACT JAMRIS-SIJ).

Otobo TM, Conaghan PG, Maksymowych WP, van der Heijde D, Weiss P, Sudol-Szopinska I, Herregods N, Jaremko JL, Meyers AB, Rumsey D, Inarejos EC, Kirkhus E, Stimec J, Panwar J, Thorpe K, Jans L, van Rossum MA, Tolend M, Perez M, Tzaribachev N, Sandhya P, Tse S, Appenzeller S, Swami VG, Touma Z, Lambert R, Doria AS.

J Rheumatol. 2019 Feb 15. pii: jrheum.181115. doi: 10.3899/jrheum.181115. [Epub ahead of print]

PMID:
30770500
20.

Clinical Characteristics of Patients with Spondyloarthritis in Japan in Comparison with Other Regions of the World.

Kishimoto M, Yoshida K, Ichikawa N, Inoue H, Kaneko Y, Kawasaki T, Matsui K, Morita M, Suda M, Tada K, Takizawa N, Tamura N, Taniguchi A, Taniguchi Y, Tsuji S, Haji Y, Rokutanda R, Yanaoka H, Cheung PP, Gu J, Kim TH, Luo SF, Okada M, López Medina C, Molto A, Dougados M, Kobayashi S, van der Heijde D, Tomita T.

J Rheumatol. 2019 Feb 15. pii: jrheum.180412. doi: 10.3899/jrheum.180412. [Epub ahead of print]

PMID:
30770497
21.

Validity of the rheumatoid arthritis MRI score applied to the forefeet using the OMERACT filter: a systematic literature review.

Dakkak YJ, van der Heijde DM, Reijnierse M, van der Helm-van Mil AHM.

RMD Open. 2018 Dec 5;4(2):e000796. doi: 10.1136/rmdopen-2018-000796. eCollection 2018.

22.

Individual-level and country-level socioeconomic determinants of disease outcomes in SpA: multinational, cross-sectional study (ASAS-COMOSPA).

Putrik P, Ramiro S, Moltó A, Keszei AP, Norton S, Dougados M, van der Heijde D, Landewé RBM, Boonen A.

Ann Rheum Dis. 2019 Apr;78(4):486-493. doi: 10.1136/annrheumdis-2018-214259. Epub 2019 Jan 23.

PMID:
30674477
23.

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.

van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Gruben D, Wallenstein G, Connell CA, Fleischmann R; ORAL Scan Investigators.

Arthritis Rheumatol. 2019 Jun;71(6):878-891. doi: 10.1002/art.40803. Epub 2019 Apr 24.

24.

Report from the Hand Osteoarthritis Working Group at OMERACT 2018: Update on Core Instrument Set Development.

Wittoek R, Kroon FPB, Kundakci B, Abhishek A, Haugen IK, Berenbaum F, Conaghan PG, Ishimori ML, Smeets W, van der Heijde D, Kloppenburg M.

J Rheumatol. 2019 Jan 15. pii: jrheum.181003. doi: 10.3899/jrheum.181003. [Epub ahead of print]

PMID:
30647176
25.

Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.

Ishiguro N, Tanaka Y, Yamanaka H, Yoneda T, Ohira T, Okubo N, Genant HK, van der Heijde D, Takeuchi T.

Rheumatology (Oxford). 2019 Jun 1;58(6):997-1005. doi: 10.1093/rheumatology/key416.

26.

Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study.

Webers C, Ramiro S, Landewé R, van der Heijde D, van den Bosch F, Dougados M, van Tubergen A, Boonen A.

RMD Open. 2018 Nov 27;4(2):e000766. doi: 10.1136/rmdopen-2018-000766. eCollection 2018.

27.

Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial.

Nordberg LB, Lillegraven S, Aga AB, Sexton J, Olsen IC, Lie E, Berner Hammer H, Uhlig T, van der Heijde D, Kvien TK, Haavardsholm EA.

RMD Open. 2018 Nov 16;4(2):e000752. doi: 10.1136/rmdopen-2018-000752. eCollection 2018.

28.

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies.

Braun J, Deodhar A, Landewé R, Baraliakos X, Miceli-Richard C, Sieper J, Quebe-Fehling E, Martin R, Porter B, Gandhi KK, van der Heijde D; MEASURE 1 and MEASURE 2 study groups.

RMD Open. 2018 Nov 21;4(2):e000749. doi: 10.1136/rmdopen-2018-000749. eCollection 2018.

29.

Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis.

Kloppenburg M, Peterfy C, Haugen IK, Kroon F, Chen S, Wang L, Liu W, Levy G, Fleischmann RM, Berenbaum F, van der Heijde D, Bansal P, Wittoek R, Feng S, Fang Y, Saltarelli M, Medema JK, Levesque MC.

Ann Rheum Dis. 2019 Mar;78(3):413-420. doi: 10.1136/annrheumdis-2018-213336. Epub 2018 Dec 14.

30.

Is active sacroiliitis on MRI associated with radiographic damage in axial spondyloarthritis? Real-life data from the ASAS and DESIR cohorts.

Sepriano A, Ramiro S, Landewé R, Dougados M, van der Heijde D, Rudwaleit M.

Rheumatology (Oxford). 2018 Dec 12. doi: 10.1093/rheumatology/key387. [Epub ahead of print]

PMID:
30544144
31.

Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life.

Imkamp M, Lima Passos V, Boonen A, Arends S, Dougados M, Landewé R, Ramiro S, Van den Bosch F, van der Heijde D, Wink FR, Spoorenberg A, van Tubergen A.

RMD Open. 2018 Nov 14;4(2):e000755. doi: 10.1136/rmdopen-2018-000755. eCollection 2018.

32.

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.

van der Heijde D, Baraliakos X, Gensler LS, Maksymowych WP, Tseluyko V, Nadashkevich O, Abi-Saab W, Tasset C, Meuleners L, Besuyen R, Hendrikx T, Mozaffarian N, Liu K, Greer JM, Deodhar A, Landewé R.

Lancet. 2018 Dec 1;392(10162):2378-2387. doi: 10.1016/S0140-6736(18)32463-2. Epub 2018 Oct 22.

33.

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.

van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group.

Lancet. 2018 Dec 8;392(10163):2441-2451. doi: 10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22.

PMID:
30360964
34.

Spinal radiographic progression in early axial Spondyloarthritis: Five-year results from the DESIR cohort.

Ramiro S, van der Heijde D, Sepriano A, van Lunteren M, Moltó A, Feydy A, d'Agostino MA, Loeuille D, Dougados M, Reijnierse M, Claudepierre P.

Arthritis Care Res (Hoboken). 2018 Oct 24. doi: 10.1002/acr.23796. [Epub ahead of print]

PMID:
30354022
35.

Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry.

Mease PJ, van der Heijde D, Karki C, Liu M, Park Y, Greenberg JD.

Rheumatol Ther. 2018 Dec;5(2):537-550. doi: 10.1007/s40744-018-0129-z. Epub 2018 Oct 23.

36.

Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort.

Ortolan A, van Lunteren M, Ramiro S, Ramonda R, Landewé RBM, Dagfinrud H, Jacobsson LTH, van der Heijde D, van Gaalen FA.

Arthritis Res Ther. 2018 Oct 1;20(1):218. doi: 10.1186/s13075-018-1705-x.

37.

Validation and reliability of translation of the ASAS Health Index in a Colombian Spanish-speaking population with spondyloarthritis.

Bautista-Molano W, Landewé RBM, Kiltz U, Valle-Oñate R, van der Heijde D.

Clin Rheumatol. 2018 Nov;37(11):3063-3068. doi: 10.1007/s10067-018-4308-7. Epub 2018 Sep 26.

PMID:
30259248
38.

Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?

Michelsen B, Sexton J, Smolen JS, Aletaha D, Krogh NS, van der Heijde D, Kvien TK, Hetland ML.

Ann Rheum Dis. 2018 Dec;77(12):1736-1741. doi: 10.1136/annrheumdis-2018-213463. Epub 2018 Sep 20.

PMID:
30237203
39.

Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.

Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, Zhou Y, Leu JH, Campbell K, Sweet K, Harrison DD, Hsia EC, van der Heijde D.

Arthritis Rheumatol. 2019 Feb;71(2):258-270. doi: 10.1002/art.40728. Epub 2018 Dec 29.

PMID:
30225992
40.

Is it Useful to Repeat Magnetic Resonance Imaging of the Sacroiliac Joints After Three Months or One Year in the Diagnosis of Patients With Chronic Back Pain and Suspected Axial Spondyloarthritis?

Bakker PAC, Ramiro S, Ez-Zaitouni Z, van Lunteren M, Berg IJ, Landewé R, Ramonda R, van Oosterhout M, Reijnierse M, van Gaalen FA, van der Heijde D.

Arthritis Rheumatol. 2019 Mar;71(3):382-391. doi: 10.1002/art.40718. Epub 2019 Feb 6.

41.

Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey.

Roodenrijs NMT, de Hair MJH, van der Goes MC, Jacobs JWG, Welsing PMJ, van der Heijde D, Aletaha D, Dougados M, Hyrich KL, McInnes IB, Mueller-Ladner U, Senolt L, Szekanecz Z, van Laar JM, Nagy G; whole EULAR Task Force on development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis.

Ann Rheum Dis. 2018 Dec;77(12):1705-1709. doi: 10.1136/annrheumdis-2018-213687. Epub 2018 Sep 7.

PMID:
30194273
42.

Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis.

Ferreira RJO, Ndosi M, de Wit M, Santos EJF, Duarte C, Jacobs JWG, Machado PM, van der Heijde D, Gossec L, da Silva JAP.

Ann Rheum Dis. 2018 Aug 20. pii: annrheumdis-2018-214199. doi: 10.1136/annrheumdis-2018-214199. [Epub ahead of print] No abstract available.

PMID:
30127056
43.

Performance of the Michigan Hand Outcomes Questionnaire in hand osteoarthritis.

Kroon FPB, Boersma A, Boonen A, van Beest S, Damman W, van der Heijde D, Rosendaal FR, Kloppenburg M.

Osteoarthritis Cartilage. 2018 Dec;26(12):1627-1635. doi: 10.1016/j.joca.2018.07.018. Epub 2018 Aug 9.

PMID:
30099114
44.

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.

Stamm TA, Machold KP, Aletaha D, Alasti F, Lipsky P, Pisetsky D, Landewe R, van der Heijde D, Sepriano A, Aringer M, Boumpas D, Burmester G, Cutolo M, Ebner W, Graninger W, Huizinga T, Schett G, Schulze-Koops H, Tak PP, Martin-Mola E, Breedveld F, Smolen J.

Arthritis Res Ther. 2018 Aug 9;20(1):174. doi: 10.1186/s13075-018-1667-z.

45.

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study.

van der Heijde D, Durez P, Schett G, Naredo E, Østergaard M, Meszaros G, De Leonardis F, de la Torre I, López-Romero P, Schlichting D, Nantz E, Fleischmann R.

Clin Rheumatol. 2018 Sep;37(9):2381-2390. doi: 10.1007/s10067-018-4221-0. Epub 2018 Aug 4.

46.
47.

Which scoring method depicts spinal radiographic damage in early axial spondyloarthritis best? Five-year results from the DESIR cohort.

Ramiro S, Claudepierre P, Sepriano A, van Lunteren M, Molto A, Feydy A, Antonietta d'Agostino M, Loeuille D, Dougados M, Reijnierse M, van der Heijde D.

Rheumatology (Oxford). 2018 Nov 1;57(11):1991-2000. doi: 10.1093/rheumatology/key185.

PMID:
30053219
48.

Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol.

Paulshus Sundlisæter N, Olsen IC, Aga AB, Hammer HB, Uhlig T, van der Heijde D, Kvien TK, Lillegraven S, Haavardsholm EA; ARCTIC study group.

Rheumatology (Oxford). 2018 Nov 1;57(11):2022-2031. doi: 10.1093/rheumatology/key202.

PMID:
30053199
49.

Employment and the role of personal factors among patients with ankylosing spondylitis: a Dutch cross-sectional case-control study.

Webers C, Vanhoof L, van Genderen S, Heuft L, van de Laar M, Luime J, van der Heijde D, van Gaalen FA, Spoorenberg A, Boonen A.

RMD Open. 2018 Jun 27;4(1):e000680. doi: 10.1136/rmdopen-2018-000680. eCollection 2018.

50.

Response to: 'Inconsistency between supplement and article?' by Babaoglu H.

van der Heijde D, de Peyrecave N, Nurminen T.

Ann Rheum Dis. 2019 Aug;78(8):e85. doi: 10.1136/annrheumdis-2018-213887. Epub 2018 Jul 10. No abstract available.

PMID:
29991474

Supplemental Content

Loading ...
Support Center